Bluebird Bio Inc. (BLUE) Given Consensus Rating of “Buy” by Analysts
Shares of Bluebird Bio Inc. (NASDAQ:BLUE) have received an average rating of “Buy” from the nineteen ratings firms that are covering the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $84.39.
BLUE has been the subject of a number of recent research reports. Roth Capital initiated coverage on shares of Bluebird Bio in a research note on Thursday, September 22nd. They set a “buy” rating and a $87.00 price objective for the company. Goldman Sachs Group Inc. upgraded shares of Bluebird Bio from a “buy” rating to a “conviction-buy” rating and set a $135.00 target price for the company in a research note on Thursday, September 15th. Cantor Fitzgerald downgraded shares of Bluebird Bio from a “hold” rating to a “sell” rating and cut their target price for the company from $65.24 to $37.00 in a research note on Friday, October 14th. Leerink Swann raised their target price on shares of Bluebird Bio from $67.00 to $80.00 and gave the company an “outperform” rating in a research note on Friday, October 14th. Finally, Maxim Group reiterated a “buy” rating and issued a $85.00 target price (down from $105.00) on shares of Bluebird Bio in a research note on Thursday, August 4th.
Bluebird Bio (NASDAQ:BLUE) opened at 56.85 on Wednesday. Bluebird Bio has a 52 week low of $35.37 and a 52 week high of $95.28. The company’s 50-day moving average price is $58.56 and its 200 day moving average price is $51.38. The company’s market capitalization is $2.12 billion.
Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported ($2.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.59) by $0.48. Bluebird Bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The business had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.82 million. During the same quarter in the prior year, the company earned ($1.18) earnings per share. The company’s quarterly revenue was up 17.4% on a year-over-year basis. On average, analysts predict that Bluebird Bio will post ($6.99) EPS for the current year.
In related news, insider Eric Sullivan sold 416 shares of Bluebird Bio stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $67.00, for a total value of $27,872.00. Following the transaction, the insider now directly owns 5,891 shares of the company’s stock, valued at $394,697. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.50% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in BLUE. Seven Eight Capital LLC purchased a new position in shares of Bluebird Bio during the first quarter worth about $108,000. Quantbot Technologies LP boosted its position in shares of Bluebird Bio by 431.3% in the second quarter. Quantbot Technologies LP now owns 2,848 shares of the company’s stock worth $123,000 after buying an additional 2,312 shares during the period. First Mercantile Trust Co. purchased a new position in shares of Bluebird Bio during the third quarter worth about $129,000. Sei Investments Co. boosted its position in shares of Bluebird Bio by 106.7% in the third quarter. Sei Investments Co. now owns 2,515 shares of the company’s stock worth $170,000 after buying an additional 1,298 shares during the period. Finally, Winslow Evans & Crocker Inc. boosted its position in shares of Bluebird Bio by 170.0% in the third quarter. Winslow Evans & Crocker Inc. now owns 2,700 shares of the company’s stock worth $183,000 after buying an additional 1,700 shares during the period.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Stock Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related stocks with our FREE daily email newsletter.